VYNE Therapeutics Inc. (VYNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
VYNE POWR Grades
- Sentiment is the dimension where VYNE ranks best; there it ranks ahead of 94.17% of US stocks.
- VYNE's strongest trending metric is Growth; it's been moving up over the last 179 days.
- VYNE's current lowest rank is in the Stability metric (where it is better than 6.96% of US stocks).
VYNE Stock Summary
- With a year-over-year growth in debt of -99%, VYNE Therapeutics Inc's debt growth rate surpasses only 1.61% of about US stocks.
- The volatility of VYNE Therapeutics Inc's share price is greater than that of 98.58% US stocks with at least 200 days of trading history.
- VYNE Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -104.61%, greater than the shareholder yield of only 3.69% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to VYNE Therapeutics Inc, a group of peers worth examining would be LKCO, NSPR, TUFN, BNFT, and QMCO.
- VYNE's SEC filings can be seen here. And to visit VYNE Therapeutics Inc's official web site, go to www.menlotherapeutics.com.
VYNE Valuation Summary
- VYNE's EV/EBIT ratio is -0.2; this is 100.68% lower than that of the median Healthcare stock.
- Over the past 44 months, VYNE's price/sales ratio has gone down 907.3.
- Over the past 44 months, VYNE's price/sales ratio has gone down 907.3.
Below are key valuation metrics over time for VYNE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VYNE | 2021-08-31 | 5.5 | 1.2 | -1.0 | -0.2 |
| VYNE | 2021-08-30 | 5.5 | 1.2 | -1.0 | -0.2 |
| VYNE | 2021-08-27 | 5.3 | 1.1 | -1.0 | -0.2 |
| VYNE | 2021-08-26 | 4.9 | 1.0 | -0.9 | -0.1 |
| VYNE | 2021-08-25 | 5.1 | 1.1 | -0.9 | -0.1 |
| VYNE | 2021-08-24 | 5.1 | 1.1 | -0.9 | -0.1 |
VYNE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VYNE has a Quality Grade of D, ranking ahead of 14.91% of graded US stocks.
- VYNE's asset turnover comes in at 0.132 -- ranking 235th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows VYNE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.132 | 0.856 | -2.324 |
| 2021-03-31 | 0.194 | 0.926 | -5.086 |
| 2020-12-31 | 0.170 | 0.934 | -4.672 |
| 2020-09-30 | 0.140 | 0.949 | -4.901 |
| 2020-06-30 | 0.115 | 0.964 | -4.606 |
| 2020-03-31 | 0.016 | 0.845 | -1.853 |
VYNE Price Target
For more insight on analysts targets of VYNE, see our VYNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.58 (Moderate Buy) |
VYNE Stock Price Chart Interactive Chart >
VYNE Price/Volume Stats
| Current price | $0.40 | 52-week high | $4.24 |
| Prev. close | $0.41 | 52-week low | $0.34 |
| Day low | $0.38 | Volume | 365,800 |
| Day high | $0.43 | Avg. volume | 998,645 |
| 50-day MA | $0.54 | Dividend yield | N/A |
| 200-day MA | $1.02 | Market Cap | 23.15M |
VYNE Therapeutics Inc. (VYNE) Company Bio
VYNE Therapeutics Inc. operates as a clinical stage bio-pharmaceutical company. The Company develops medicines and therapies for the treatment of chronic pruritus and cough. VYNE Therapeutics serves customers worldwide.
Latest VYNE News From Around the Web
Below are the latest news stories about VYNE Therapeutics Inc that investors may wish to consider to help them evaluate VYNE as an investment opportunity.
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic DermatitisSystemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared to the lowest commercially available oral alternative Findings from Phase 1b safety portion of study support trial continuation Topline Phase 2a results expected in Q1 2022 BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics I |
VYNE Therapeutics Divests Topical Minocycline AssetsTransaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) |
VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access EventBRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. T |
Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?Investors need to pay close attention to for VYNE Therapeutics (VYNE) stock based on the movements in the options market lately. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
VYNE Price Returns
| 1-mo | -18.96% |
| 3-mo | -27.06% |
| 6-mo | -62.62% |
| 1-year | -89.01% |
| 3-year | -98.55% |
| 5-year | N/A |
| YTD | -60.78% |
| 2021 | -83.86% |
| 2020 | -65.95% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...